Cowen & Co. analyst Eric Schmidt reiterated a Buy rating on BeiGene Ltd (NASDAQ: BGNE) today. The company’s shares opened today at $174.69.
According to TipRanks.com, Schmidt is a top 25 analyst with an average return of 45.1% and a 64.6% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Merrimack Pharmaceuticals, Adaptimmune Therapeutics, and Alexion Pharmaceuticals.
BeiGene Ltd has an analyst consensus of Strong Buy, with a price target consensus of $208.33.
See today’s analyst top recommended stocks >>
Based on BeiGene Ltd’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $105 million. In comparison, last year the company had a GAAP net loss of $50.69 million.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BGNE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BeiGene Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of biopharmaceutical products. It develops immuno-oncology drugs for cancer treatment. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.
